Pathological anti-beta-1-adrenergic receptor autoantibody (beta1-AAB) (beta1-AAB)

Pathological anti-beta-1-adrenergic receptor autoantibodies are functional immunoglobulins that act as long-acting agonists of the beta-1 adrenergic receptor (ADRB1) in the heart (Jahns et al., 2004, Circulation). Unlike natural ligands like norepinephrine, these autoantibodies induce persistent receptor activation without typical desensitization, leading to chronic intracellular calcium overload and cardiomyocyte apoptosis (Wallukat & Schimke, 2014, Frontiers in Bioscience). This chronic signaling is a key driver in the development and progression of dilated cardiomyopathy (DCM) and chronic heart failure (Boivin et al., 2015, European Journal of Heart Failure). These antibodies are found in approximately 30-80% of patients with DCM, serving as both a biomarker and a therapeutic target. Therapeutic strategies include the use of cyclic decoy peptides like COR-1 or DNA aptamers like BC 007 to neutralize the antibodies in the bloodstream (Berlin Cures, 2023). Additionally, immunoadsorption therapy is used to physically remove these autoantibodies, which has been shown to improve cardiac function and patient outcomes in clinical trials. Targeting these autoantibodies represents a precision medicine approach for heart failure patients with an underlying autoimmune pathology.

Other names

Anti-beta-1-adrenergic receptor antibodyBeta-1-adrenoceptor autoantibodyAgonistic anti-beta-1-AR antibodyADRB1 autoantibodyAnti-beta-1-AR autoantibody

Neutralization of circulating autoantibodies via decoy peptides or aptamers to prevent receptor overstimulation; physical removal from plasma via immunoadsorption.